Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which ...

Amid the sultry summer months, a few signs of fall become apparent, such as the appearance of school supplies on stores ...

Osivax has released phase 2a trial data confirming that its broad-spectrum flu vaccine candidate, OVX836, can be safely ...

TruCan Ultra CIV H3N2/H3N8 will broadly protect canine patients from canine influenza. Elanco Animal Health Incorporated ...

Infectious disease specialist Monica Gandhi, MD examines recent claims about the safety of thimerosal, a preservative used in ...

A CDC advisory panel vote to recommend against use of seasonal influenza vaccines containing small amounts of thimerosal ...

At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

Cumberland resident Dr. Judy Stone is an infectious disease specialist who spent 25 years in solo practice in Allegany County ...

Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profileRobust complementary immune responses were ...

Osivax publishes phase 2a results of OVX836-004 study; supports co-administration of OVX836 with seasonal flu vaccine: Lyon, France Saturday, July 12, 2025, 18:00 Hrs [IST] Osivax ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.